Join Growin Stock Community!

Zevra therapeutics, inc.ZVRA.US Overview

US StockHealthcare
(No presentation for ZVRA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ZVRA AI Insights

ZVRA Overall Performance

ZVRA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ZVRA Recent Performance

-1.87%

Zevra therapeutics, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

ZVRA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ZVRA Key Information

ZVRA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ZVRA Profile

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Price of ZVRA

ZVRA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ZVRA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.63
PE Ratio (TTM)
19.00
Forward PE
74.69
PS Ratio (TTM)
5.96
PB Ratio
3.84
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
80.65%
Net Margin
41.86%
Revenue Growth (YoY)
240.47%
Profit Growth (YoY)
306.67%
3-Year Revenue Growth
108.54%
3-Year Profit Growth
108.65%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.63
PE Ratio (TTM)
19.00
Forward PE
74.69
PS Ratio (TTM)
5.96
PB Ratio
3.84
Price-to-FCF
-
Gross Margin
80.65%
Net Margin
41.86%
Revenue Growth (YoY)
240.47%
Profit Growth (YoY)
306.67%
3-Year Revenue Growth
108.54%
3-Year Profit Growth
108.65%

  • When is ZVRA's latest earnings report released?

    The most recent financial report for Zevra therapeutics, inc. (ZVRA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ZVRA's short-term business performance and financial health. For the latest updates on ZVRA's earnings releases, visit this page regularly.

  • Where does ZVRA fall in the P/E River chart?

    According to historical valuation range analysis, Zevra therapeutics, inc. (ZVRA)'s current price-to-earnings (P/E) ratio is 16.05, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of ZVRA?

    According to the latest financial report, Zevra therapeutics, inc. (ZVRA) reported an Operating Profit of 4.14M with an Operating Margin of 15.9% this period, representing a growth of 115.17% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ZVRA's revenue growth?

    In the latest financial report, Zevra therapeutics, inc. (ZVRA) announced revenue of 26.06M, with a Year-Over-Year growth rate of 605.36%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ZVRA have?

    As of the end of the reporting period, Zevra therapeutics, inc. (ZVRA) had total debt of 62.72M, with a debt ratio of 0.23. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ZVRA have?

    At the end of the period, Zevra therapeutics, inc. (ZVRA) held Total Cash and Cash Equivalents of 54.44M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ZVRA go with three margins increasing?

    In the latest report, Zevra therapeutics, inc. (ZVRA) did not achieve the “three margins increasing” benchmark, with a gross margin of 95.2%%, operating margin of 15.9%%, and net margin of -2.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ZVRA's profit trajectory and future growth potential.

  • Is ZVRA's EPS continuing to grow?

    According to the past four quarterly reports, Zevra therapeutics, inc. (ZVRA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ZVRA?

    Zevra therapeutics, inc. (ZVRA)'s Free Cash Flow (FCF) for the period is 4.74M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 126.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.